Publications by authors named "Tournev I"

Article Synopsis
  • * Results showed that the minor T allele is more frequent in patients with sALS than in control groups, indicating a potential link to increased disease susceptibility.
  • * However, the impact of this variant on the age at which symptoms begin was inconclusive, suggesting that while T allele carriers might experience symptoms around 2.5 years earlier, the findings need to be verified with larger sample sizes.
View Article and Find Full Text PDF

Sarcoglycanopathies are among the most frequent and severe forms of autosomal recessive forms of limb-girdle muscular dystrophies (LGMDs) with childhood onset. Four subtypes are known: LGMDR3, LGMDR4, LGMDR5 and LGMDR6, which are caused, respectively, by mutations in the , SGCB, and genes. We present the clinical variability of LGMD 2C/R5 among a genetically homogeneous group of 57 patients, belonging to 35 pedigrees.

View Article and Find Full Text PDF

Charcot-Marie-Tooth neuropathy type 4D (CMT4D) is a rare genetic disorder of the peripheral nervous system caused by biallelic mutations in the N-Myc Downstream Regulated 1 gene (). Patients present with an early onset demyelinating peripheral neuropathy causing severe distal muscle weakness and sensory loss, leading to loss of ambulation and progressive sensorineural hearing loss. The disorder was initially described in the Roma community due to a common founder mutation, and only a handful of disease-causing variants have been described in this gene so far.

View Article and Find Full Text PDF

Background: Autosomal recessive spastic ataxia ofCharlevoix-Saguenay (ARSACS) is a rare neurodegenerative disorder characterizedby early-onset cerebellar ataxia, peripheral sensorimotor neuropathy, and lowerlimb spasticity. We present clinical andgenetic data of the first Bulgarian patients diagnosed with ARSACS by wholeexome sequencing (WES).

Methods: Variant filtering was performed usinglocally established pipeline and the selected variants were analysed by Sangersequencing.

View Article and Find Full Text PDF
Article Synopsis
  • Congenital myasthenic syndromes (CMS) are inherited conditions causing muscle weakness and fatigue, and this study focuses on patients with a specific genetic mutation (c.1327delG in the CHRNE gene) linked to CHRNE-CMS.* -
  • The research involved 91 Bulgarian Roma patients and assessed various symptoms such as ocular issues and muscle weakness using standardized tests and patient-reported measures, categorizing severity into mild, moderate, and severe levels.* -
  • Results indicated notable variability in symptoms among patients, including consistent bulbar weakness and permanent diplopia, while severe cases showed more significant respiratory function impairment, highlighting the diverse clinical presentation of this genetic mutation.*
View Article and Find Full Text PDF

Purpose: An increasing number of patients with Duchenne muscular dystrophy (DMD) now have access to improved standard of care and disease modifying treatments, which improve the clinical course of DMD and extend life expectancy beyond 30 years of age. A key issue for adolescent DMD patients is the transition from paediatric- to adult-oriented healthcare. Adolescents and adults with DMD have unique but highly complex healthcare needs associated with long-term steroid use, orthopaedic, respiratory, cardiac, psychological, and gastrointestinal problems meaning that a comprehensive transition process is required.

View Article and Find Full Text PDF

Background: Congenital myasthenic syndromes (CMS) are a group of inherited neuromuscular junction (NMJ) disorders arising from gene variants encoding diverse NMJ proteins. Recently, the VAMP1 gene, responsible for encoding the vesicle-associated membrane protein 1 (VAMP1), has been associated with CMS.

Methods: This study presents a characterization of five new individuals with VAMP1-related CMS, providing insights into the phenotype.

View Article and Find Full Text PDF

Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network community detection analysis of complementary biomedical information provided by relevant data sources, namely protein-protein interactions, pathways and metabolomics.

View Article and Find Full Text PDF
Article Synopsis
  • Transthyretin amyloidosis (ATTR amyloidosis) has both cardiac and neurological symptoms, with a growing recognition of a mixed phenotype among patients.
  • A study from the Transthyretin Amyloidosis Outcomes Survey (THAOS) found that about one-third of symptomatic patients were classified as having a mixed phenotype, with most cases being hereditary ATTR.
  • The research indicates that the mixed phenotype may be more common than previously understood, highlighting the importance of comprehensive evaluations for all ATTR amyloidosis patients throughout their treatment.
View Article and Find Full Text PDF

We report two unrelated Bulgarian families with hereditary transthyretin (ATTR) amyloidosis due to a rare p.Glu74Leu (Glu54Leu) pathogenic variant found in seven individuals-three of them symptomatic. Only one family with the same variant and with a Swedish origin has been clinically described so far.

View Article and Find Full Text PDF

Introduction: Fingolimod, a sphingosine-1-phosphate receptor agonist used for the treatment of multiple sclerosis (MS). Our goal was to assess the impact of fingolimod on quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) after 2 years of treatment in this real-world study.

Patients And Methods: This was a 2-year, prospective, observational study conducted in Bulgaria in RRMS patients treated with fingolimod.

View Article and Find Full Text PDF

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by wide clinical and biological heterogeneity, with a large proportion of ALS patients also exhibiting frontotemporal dementia (FTD) spectrum symptoms. This project aimed to characterize risk subtypes of the H1 haplotype within the (microtubule-associated protein tau) gene, according to their possible effect as a risk factor and as a modifying factor in relation to the age of disease onset. One hundred patients from Bulgaria with sporadic ALS were genotyped for the variants rs1467967, rs242557, rs1800547, rs3785883, rs2471738, and rs7521.

View Article and Find Full Text PDF
Article Synopsis
  • Transthyretin amyloidosis (ATTR amyloidosis) is a serious, progressive disease caused by the buildup of transthyretin amyloid fibrils in the body's tissues and organs, and can be hereditary or wild-type.* -
  • The Transthyretin Amyloidosis Outcomes Survey (THAOS) is a major global study launched in 2007 that has tracked over 6,000 patients, including symptomatic patients and asymptomatic carriers, providing important data on the disease's characteristics.* -
  • The recent analysis from THAOS revealed that most symptomatic patients are male, with a shift toward more mixed phenotypes and less predominantly cardiac phenotypes, highlighting the disease's complexity and variability among
View Article and Find Full Text PDF

Purpose: The transthyretin kinetic stabilizer tafamidis, used as a first-line therapy of amyloidosis patients, binds selectively to the transthyretin protein structure and thus prevents its dissociation. The limited information regarding tafamidis application in Glu89Gln amyloidosis patients imposed our research team to determine and evaluate its individual mean plasma levels and their biological variation.

Methods: The present cohort study investigated Bulgarian amyloidosis patients, grouped by gender, age, and therapy duration.

View Article and Find Full Text PDF

Dominant mutations in tyrosyl-tRNA synthetase (YARS1) and six other tRNA ligases cause Charcot-Marie-Tooth peripheral neuropathy (CMT). Loss of aminoacylation is not required for their pathogenicity, suggesting a gain-of-function disease mechanism. By an unbiased genetic screen in Drosophila, we link YARS1 dysfunction to actin cytoskeleton organization.

View Article and Find Full Text PDF

Objectives: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of motor function, disability, and death. Variants in the gene, encoding the Profilin-1 protein, are related to ALS18.

Methods: We present a pedigree consisting of 3 generations and 4 affected individuals, 3 of which carry a novel heterozygous variant: c.

View Article and Find Full Text PDF

Arginase deficiency is an autosomal recessive urea cycle disorder caused by pathogenic variants in the gene. The clinical features of the disease include spasticity, tremour, ataxia, hypotonia, microcephaly and seizures. Growth delay can also be observed in the affected individuals.

View Article and Find Full Text PDF

Background: Telemedicine (TM) contributes to bridge the gap between healthcare facilities and patients' homes with neuromuscular disease (NMD) because of mobility issues. However, its deployment is limited due to difficulties evaluating subtle neurological signs such as mild weakness or sensory deficits. The COVID-19 pandemic has disrupted healthcare delivery worldwide, necessitating rapid measures implementation by health care providers (HCPs) to protect patients from acquiring SARS-CoV-2 while maintaining the best care and treatment.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated vutrisiran, an RNA therapy aimed at reducing transthyretin (TTR) production, in patients with hereditary transthyretin (ATTRv) amyloidosis affecting the nerves.
  • The phase 3 HELIOS-A trial involved 164 patients, comparing vutrisiran (administered every 3 months) to patisiran (administered every 3 weeks) and an external placebo group, assessing various health outcomes over 18 months.
  • Results showed that vutrisiran led to significant improvements in neuropathy scores and quality of life compared to placebo, with a good safety profile and no serious drug-related complications.*
View Article and Find Full Text PDF

Unlabelled: Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare, autosomal-dominant (AD) multisystem disorder resulting from the extracellular deposition of amyloid fibrils formed by a destabilized mutant form of transthyretin (TTR), a transport protein predominantly produced by the liver.

Aim: The aims of the current study are to demonstrate the Bulgarian experience with the screening programs among the high-risk patient population over the last 7 years, to present the results from the therapy with TTR stabilizer in our cohort, as well as to stress on the importance of a follow-up of asymptomatic carriers with TTR pathogenic variants by a multidisciplinary team of specialists.

Materials And Methods: In 2014, a screening program among the high-risk patient population for ATTRv was initiated in Bulgaria.

View Article and Find Full Text PDF

Present study describes a high-performance liquid chromatography method for the determination of the potent kinetic stabilizer-Tafamidis in human plasma. It was approved for medical use in European Union in 2011. Ultra violet (UV) detection mode and isocratic elution of the mobile phase were set and made the analytical procedure fast and widely applicable.

View Article and Find Full Text PDF

Transthyretin amyloid (ATTR) amyloidosis is a rare disorder with an adult-onset defined by the accumulation of misfolded fibrils predominantly in peripheral nerves, the heart, and the digestive tract. The disease is characterized by two forms - hereditary (ATTRv) or acquired (ATTRwt). Various point mutations in the transthyretin gene induce the hereditary form of the disease.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the differences between male and female patients with ATTRv amyloidosis, a serious heart disease caused by amyloid buildup.
  • It analyzes data from the THAOS survey, focusing on cardiac symptoms, genotype, and phenotype differences linked to sex among patients.
  • Results show that males are more likely to have severe cardiac symptoms and may have biological factors that increase their risk for heart involvement compared to females.
View Article and Find Full Text PDF